taVNS on the Inpatient Psychiatric Unit

Depression, Anxiety Clinical Trial

Official title:

Managing Inpatient Neuropsychiatric Conditions Using Wearable Auricular Vagus Stimulation: The iWAVE Pilot Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05791383
• Other study ID #: 00120876
• Status: Recruiting
• Phase: N/A
• Start date: December 1, 2022
• Est. completion date: December 2024

Study information

• Verified date: February 2024
• Source: Medical University of South Carolina
• Contact: Bashar W Badran, PhD
• Phone: 843-792-6076
• Email: badran[@]musc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a research study to find out if mental health symptoms in patients admitted to the Institute of Psychiatry are affected by a form of ear stimulation called transcutaneous auricular vagus nerve stimulation, or taVNS. Participants will receive ear stimulation during their inpatient treatment at the Institute of Psychiatry. Participants will be randomly assigned to either receive ear stimulation for 1 day (up to 9 treatments over the course of a single day) or 3 days (up to 3 treatments per day), and will have a 50:50 chance of being in either group (like the flip of a coin). Each treatment will last up to 30 minutes and there will be a break of at least 30 minutes in between treatments. The study team will ask participants to complete a group of questionnaires at the beginning and end of the study. In addition, there are several questionnaires that will be completed daily while participants are receiving ear stimulation. Participants in the 1 day stimulation group will also receive 2 days of follow up questionnaires after the initial day of stimulation. The questionnaires will ask questions about mental health symptoms that subjects may or may not be experiencing, including questions about mood, anxiety, and sleep. The ear stimulation treatments will not interfere with the care subjects are receiving from the medical team. In order to qualify for this study, participants must be actively receiving inpatient care at the MUSC Institute of Psychiatry.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ages 18 and up

• English speaking

• Admitted to 3 North's inpatient unit in MUSC's Institute of Psychiatry (IOP)

• Have the capacity and ability to provide one's own consent and sign the informed consent document

• Primary depression diagnosis

Exclusion Criteria:

• Facial or ear pain or recent ear trauma.

• Metal implant devices in the head, heart or neck.

• History of brain surgery.

• History of myocardial infarction or arrhythmia, bradycardia.

• Acute exacerbation of a chronic respiratory disorder or acute COVID-related symptoms.

• Active GI symptoms with a history of diabetes mellitus or history of gastroparesis secondary to diabetes mellitus.

• Personal or family history of seizure or epilepsy or personal use of medications that substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium).

• Personal history of head injury, concussion, or self-report of moderate to severe traumatic brain injury.

• Individuals suffering from frequent/severe headaches.

• Individuals with a reported history of psychosis or mania, or individuals who are actively manic or psychotic.

• Individuals who are catatonic or otherwise unable to participate in the informed consent process.

• Moderate to severe alcohol or substance use disorder.

• Pregnancy

Related Conditions & MeSH terms

• Depression
• Depression, Anxiety

Intervention

Device:
• transcutaneous auricular neurostimulation
All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.

Locations

Country	Name	City	State
United States	Medical University of South Carolina Institute of Psychiatry	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Side Effect and Adverse Event Report	Subjects will be monitored for adverse effects while receiving treatments.	4 days
Secondary	General Anxiety Disorder-7 (GAD-7) Scale	Subjects will conduct pre- and post- anxiety assessments to understand if stimulation improves neuropsychiatric condition. Higher GAD-7 scores indicate higher anxiety symptoms.	4 days